Walloon

Orgenesis Provides Year End Business Update

Retrieved on: 
Monday, April 15, 2024
Education minister, Security (finance), EUR, CGT, Walloon, Growth, Pharmaceutical industry

GERMANTOWN, Md., April 15, 2024 (GLOBE NEWSWIRE) --  Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the year ended December 31, 2023.

Key Points: 
  • (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the year ended December 31, 2023.
  • “Orgenesis is a company that has set as its goal to make cell and gene therapies available and affordable.
  • Although there has been widespread acceptance of the field with multiple approvals of new products, the lack of funding has hit early-stage development companies the hardest.
  • We believe that we are now on more solid financial footing having already received collaboration payments in excess of $6 million.

Press release - Belgium Presidency debriefs EP committees on priorities

Retrieved on: 
Sunday, February 4, 2024
Pillar, Walloon, Education, Climate change, Long-Term Capital Management, Australian Space Agency, Treaty, Rape, PFAS, Policy, Ministry of Social Affairs, Blockchain, Digital identity, AMR, Natural gas, White paper, World Trade Organization, Participatory democracy, High Seas, Partnership, Artificiality, GDPR, European Social Fund Plus, Frustration, CSAM, HERA, NASA Exoplanet Archive, Housing, Safety, SME, Science policy, Government, Justice, Public health, Pesticide, Consumer protection, Mental health, European single market, API, Economy, Science, Finance, State, Commission, Violence, Culture, Artificial intelligence, Medicine, Employment, Student, Development, International trade, Woman, Fishery, Annelies Verlinden, Legislation, Digitization, Transport Select Committee, Research, Service provider, Mutagen, French Community of Belgium, Hydrogen, Death, Artificial Intelligence Act, Kool-Aid, Civil liberties, Civil service, Petra De Sutter, Scientific method, Parliament, Gender equality, Economic recovery, Mercury, Horizon, European Higher Education Area, Carcinogen, Illegal drug trade, AI, European Space Agency, Crime, Foreign Affairs, Ministry of home affairs, Creative Europe, European Health Data Space, Investment, Diversity, Work, Public administration, Food safety, Telecommunications, Farmer, Enlargement, Patent, Legal Affairs, Sport, Electricity, Health, Regional development, Conference

Ministers are holding a series of meetings in parliamentary committees to present the priorities of the Belgian Presidency of the Council.Committee on Culture and EducationCommittee on DevelopmentCommittee on Economic and Monetary AffairsCommittee on Employment and Social AffairsCommittee on the Environment, Public Health and Food SafetyCommittee on Women’s Rights and Gender EqualityCommittee on the Internal Market and Consumer ProtectionCommittee on International TradeCommittee on Industry, Research and EnergyCommittee on Legal AffairsCommittee on Civil Liberties, Justice and Home AffairsCommittee on Regional DevelopmentCommittee on Transport and Tourism Source : © European Union, 2024 - EP

Key Points: 


Ministers are holding a series of meetings in parliamentary committees to present the priorities of the Belgian Presidency of the Council.Committee on Culture and EducationCommittee on DevelopmentCommittee on Economic and Monetary AffairsCommittee on Employment and Social AffairsCommittee on the Environment, Public Health and Food SafetyCommittee on Women’s Rights and Gender EqualityCommittee on the Internal Market and Consumer ProtectionCommittee on International TradeCommittee on Industry, Research and EnergyCommittee on Legal AffairsCommittee on Civil Liberties, Justice and Home AffairsCommittee on Regional DevelopmentCommittee on Transport and Tourism Source : © European Union, 2024 - EP

Genflow Biosciences Partners with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants

Retrieved on: 
Thursday, January 18, 2024
Research, Health, Public service, SIRT6, Partnership, Quality of life, Exosome, Werner syndrome, Longevity, Therapy, Sarcopenia, Toxicity, Walloon, Messenger, Pharmaceutical industry

Continued receipt of the grants by Genflow is dependent on the parties meeting predefined criteria each applicable year.

Key Points: 
  • Continued receipt of the grants by Genflow is dependent on the parties meeting predefined criteria each applicable year.
  • Genflow, together with Revatis SA, has launched a 3-year sarcopenia research program, generously funded by new grants totalling 1.34 million euros.
  • This collaborative effort aims to expand and diversify Genflow's research pipeline, addressing this growing concern as the global population ages.
  • With the support of our partners and the backing of these two grants, we are poised to make meaningful advancements in the field of longevity."

Highlights - Visit of Belgium Presidency - Committee on Transport and Tourism

Retrieved on: 
Sunday, January 14, 2024
Civil service, Walloon, Tourism, Mobility, Service provider

Visit of Belgium Presidency

Key Points: 
  • Visit of Belgium Presidency
    12-01-2024 - 12:06
    On 23 January 2024 the TRAN Committee will welcome the Belgium Presidency: Mr Georges Gilkinet, Deputy Prime Minister and (federal) Minister of Mobility and Ms Valérie De Bue, Minister of the Civil Service, IT and Administrative Simplification of the Walloon Government, in charge of Child Benefits, Tourism, Heritage and Road Safety,
    will present to the Members the priorities of the Belgium Presidency in the field of transport and tourism, with the main focus to green and digital transition, energy security and the pathway to a zero-carbon economy.
  • The presentation of debate will take place on Tuesday afternoon 23 January 2024 from where it will be webstreamed.

Hyloris has been granted EUR 1 million in non-dilutive funding from the Walloon Region

Retrieved on: 
Thursday, June 8, 2023
Volunteering, Allergy, Overalls, Clinical trial, Quality of life, Innovation, Research, Inflammation, International trade, Wallonia, Information, Nose, EUR, Rhinorrhea, Brussels Stock Exchange, Frustration, Sneeze, Ministry of Communities and Territories Development (Ukraine), Digital, Patient, Walloon, Pharmaceutical industry, Agriculture

Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: “We are grateful for the Walloon Region’s support of innovation happening at Hyloris, and minister of Innovation Willy Borsus in particular.

Key Points: 
  • Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: “We are grateful for the Walloon Region’s support of innovation happening at Hyloris, and minister of Innovation Willy Borsus in particular.
  • This public funding will be used sparingly and prudently.”
    “Hyloris has been based in Liège for several years.
  • We have recently recruited heavily to expand our R&D team and will inaugurate an expanded lab facility in Liège in the coming weeks.
  • It occurs in around 7% of the total population, representing an estimated 19 million people in the US alone.

Telix Opens European Radiopharmaceutical Production Facility

Retrieved on: 
Thursday, June 8, 2023
Seneffe, GMP, Heart, Radiation, Employment, Therapy, Cyclotron, Education, Radionuclide, Radiopharmaceutical, Cancer, Hope, ASX, Innovation, Research, COVID, Antibody, International trade, TLX, US, Patient, Laboratory, Diagnosis, Growth, Digital, Region, Health, CNN International Europe/Middle East/Africa, Isotope, Investment, Medical imaging, Pharmaceutical industry, EU, Telix, Agriculture, Walloon

MELBOURNE, Australia and LIEGE, Belgium, June 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes Willy Borsus, Vice-President of Wallonia, Minister of Economy, Research and Innovation, Digital, Agriculture, Urban Planning and Regional Planning to officially open Telix Manufacturing Solutions, the Company's radiopharmaceutical production facility located in Brussels South (Seneffe), in the Wallonia region of Belgium.

Key Points: 
  • MELBOURNE, Australia and LIEGE, Belgium, June 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes Willy Borsus, Vice-President of Wallonia, Minister of Economy, Research and Innovation, Digital, Agriculture, Urban Planning and Regional Planning to officially open Telix Manufacturing Solutions, the Company's radiopharmaceutical production facility located in Brussels South (Seneffe), in the Wallonia region of Belgium.
  • Located in the heart of Belgium's 'Radiopharma Valley', the 2,800 square metre facility is one of Europe's largest radiopharmaceutical production facilities.
  • Often referred to as "theranostics", this approach has the potential to better inform treatment decisions and deliver personalised therapy for patients.
  • Each year more than 10 million imaging procedures are performed in the EU using radiopharmaceutical agents.

Telix Opens European Radiopharmaceutical Production Facility

Retrieved on: 
Thursday, June 8, 2023
Seneffe, GMP, Heart, Radiation, Employment, Therapy, Cyclotron, Education, Radionuclide, Radiopharmaceutical, Cancer, Hope, ASX, Innovation, Research, COVID, Antibody, International trade, TLX, US, Patient, Laboratory, Diagnosis, Growth, Digital, Region, Health, CNN International Europe/Middle East/Africa, Isotope, Investment, Medical imaging, Pharmaceutical industry, EU, Telix, Agriculture, Walloon

MELBOURNE, Australia and LIEGE, Belgium, June 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes Willy Borsus, Vice-President of Wallonia, Minister of Economy, Research and Innovation, Digital, Agriculture, Urban Planning and Regional Planning to officially open Telix Manufacturing Solutions, the Company's radiopharmaceutical production facility located in Brussels South (Seneffe), in the Wallonia region of Belgium.

Key Points: 
  • MELBOURNE, Australia and LIEGE, Belgium, June 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes Willy Borsus, Vice-President of Wallonia, Minister of Economy, Research and Innovation, Digital, Agriculture, Urban Planning and Regional Planning to officially open Telix Manufacturing Solutions, the Company's radiopharmaceutical production facility located in Brussels South (Seneffe), in the Wallonia region of Belgium.
  • Located in the heart of Belgium's 'Radiopharma Valley', the 2,800 square metre facility is one of Europe's largest radiopharmaceutical production facilities.
  • Often referred to as "theranostics", this approach has the potential to better inform treatment decisions and deliver personalised therapy for patients.
  • Each year more than 10 million imaging procedures are performed in the EU using radiopharmaceutical agents.

Myocene Announces a Successful Completion of a Bridge Round

Retrieved on: 
Monday, May 29, 2023
Exercise, Sport, Athlete, Environment, Muscle fatigue, Accident, Fatigue, Noshaq, Walloon

LIÈGE, Belgium, May 29, 2023 (GLOBE NEWSWIRE) -- Myocene, the Belgian-based sportstech company, has completed a bridge round of 2M€ in order to finalize a market-ready product, expected mid-2024.

Key Points: 
  • LIÈGE, Belgium, May 29, 2023 (GLOBE NEWSWIRE) -- Myocene, the Belgian-based sportstech company, has completed a bridge round of 2M€ in order to finalize a market-ready product, expected mid-2024.
  • Myocene is a Liège-based start-up that has developed a device for objectifying and measuring muscle fatigue.
  • This innovation, designed for top-level athletes, represents a veritable revolution in the world of sports.
  • “The Myocene device represents a profound change in the way high-level athletes are monitored," adds Dr Pierre Rigaux, Chairman and Founder.

Celyad Oncology reports full year 2022 financial results and recent business highlights

Retrieved on: 
Thursday, March 23, 2023
Intellectual property, Oncology, Probability, CET, EY, RCA, Bank statement, Article, Advanced Materials and Processes Research Institute, IP, Peter Stumpf (cellist), EDT, Sale, Research and development, CTMU, Annual report, Administration, Management, R, Research, Walloon, Cryptocurrency, Bookkeeping, Development

MONT-SAINT-GUIBERT, Belgium, March 23, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announces its financial results for the fiscal year 2022 ended December 31, 2022 and provides a business update.

Key Points: 
  • Research and Development (R&D) expenses were €18.9 million in 2022 as compared to €20.8 million in 2021, a year-over-year decrease of €1.8 million.
  • General and Administrative (G&A) expenses were €10.5 million in 2022 as compared to €9.9 million in 2021, an increase of €0.6 million.
  • A conference call will be held on Friday, March 24th at 1:00 p.m. CET / 8:00 a.m. EDT to review the financial and operating results for full year 2022.
  • Archived recording will be available in the " Events " section of the Celyad website after the event.

Renewi plc: Positive conclusion to European Commission landfill investigation

Retrieved on: 
Saturday, March 11, 2023
Wallonia, State, Walloon, Civil service commission, Mont-Saint-Guibert, Rehabilitation, EC, Subsidy, European Commission, Renewi

Renewi plc announces that the European Commission (EC) has concluded its formal investigation, first announced on 6 February 2020, into the alleged State Aid relating to the tax rate applied to certain recycled waste materials that were added to the now closed Cetem landfill in Mont Saint Guibert to contour the site for closure and rehabilitation.

Key Points: 
  • Renewi plc announces that the European Commission (EC) has concluded its formal investigation, first announced on 6 February 2020, into the alleged State Aid relating to the tax rate applied to certain recycled waste materials that were added to the now closed Cetem landfill in Mont Saint Guibert to contour the site for closure and rehabilitation.
  • In its decision published on 3 March 2023, the EC determined that the Belgian Walloon Region did not provide State Aid to Renewi Valorisation and Quarry NV.
  • In the past two years, the Belgian Walloon Region and Renewi both provided extensive information to the European Commission demonstrating that all materials used in the landfill rehabilitation were appropriate and that there was no selectivity in the Walloon Region’s treatment of Renewi.
  • Renewi is pleased this matter is now resolved and the provision of €15m taken for this liability in FY20 can be released.